Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARC-520 in chronic hepatitis B
NCT02577029Phase 2Terminated
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Dec 2015
- Primary completion
- Dec 2016
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 8
01
Overview
Phase 2, open-label trial of ARC-520 in Chronic Hepatitis B (CHB) and hepatitis D (HDV) (8 cohorts), sponsored by Arrowhead Pharmaceuticals. Primary endpoint: 1-log reduction in Hepatitis B Surface Antigen at 60 weeks. Started Dec 2015; status: terminated.
02
Drugs
ARC-520
03
Conditions
Chronic Hepatitis B (CHB)hepatitis D (HDV)
Beyond the preview
Go deeper on NCT02577029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02577029.